Food and Drug Administration approved Pylarify TruVu, improving PSMA-PET availability and reliability, enabling better prostate cancer staging, earlier recurrence detection, and broader access to advanced diagnostic imaging.

The American Academy of Neurology Annual Meeting 2026 highlighted advances in precision medicine, AI integration, gene therapies, and collaborative approaches shaping future neurological care and research.

The 30-30-30 diet promotes early protein intake and light exercise to support weight loss, but flexibility and long-term consistency remain key for sustainable results.

Rising use of semaglutide and tirzepatide highlights risks of malnutrition and bone loss, prompting clinicians to monitor nutrition, especially in vulnerable populations.

Combining pregabalin and duloxetine may improve pain control in diabetic neuropathy when monotherapy fails, enabling better symptom relief with lower doses and fewer side effects.

Individual gut microbiota differences shape metabolic responses to exercise, suggesting personalized activity plans could improve outcomes for patients with type 2 diabetes and other metabolic disorders.

FDA updates Zepbound labeling, pairing tirzepatide with KwikPen for weight management and cardiovascular risk reduction, improving usability, adherence, and access for patients, clinicians, pharmacies, and healthcare systems.

Critics say Environmental Protection Agency cost analyses omit lives saved from cleaner air, potentially weakening regulations, distorting policy decisions, and undermining public health protections and accountability.

Gastroenterology is shifting to hybrid care models combining in-person and telehealth services, aiming to reduce burnout, improve clinician autonomy, and sustain high-quality, patient-centered digestive care delivery.

Tirzepatide shows no increased risk of depression or suicidal thoughts in trials, supporting its psychological safety and giving clinicians greater confidence when prescribing weight management therapy.